Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
4.86
+0.08 (1.67%)
Market open: Aug 12, 2026, 11:23 AM EDT
4.87
+0.09 (1.88%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
| Name | Position |
|---|---|
| Dr. Jose Manuel Otero Ph.D. | Chief Operating Officer |
| Dr. Narinder P. Bhalla FACC, FSCAI, M.D. | Chief Medical Officer |
| Dr. Ronald G. Crystal M.D. | Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board |
| Mr. Keith Wonnacott | Senior Vice President of Regulatory Affairs |
| Mr. Louis Tamayo | CFO & Principal Accounting Officer |
| Mr. R. Nolan Townsend M.B.A. | CEO & Director |
| Mr. Ryan McHenry | VP & Corporate Controller |
| Ms. Ashley Kaplowitz | Head of Capital Markets |
| Date | Type | Document |
|---|---|---|
| 2026-08-12 | 8-K | lxeo-20260812.htm |
| 2026-06-29 | 8-K | lxeo-20260625.htm |
| 2026-06-15 | 8-K | lxeo-20260615.htm |
| 2026-05-11 | 8-K | lxeo-20260511.htm |
| 2026-05-11 | 10-Q | lxeo-20260331.htm |
| 2026-04-30 | 8-K | lxeo-20260428.htm |
| 2026-03-31 | S-8 | lxeo-20260330.htm |
| 2026-03-30 | 8-K | lxeo-20260330.htm |
| 2026-03-30 | 10-K | lxeo-20251231.htm |
| 2026-02-05 | 8-K | lxeo-20260130.htm |